Phase 2
Completed N=41
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Source: ClinicalTrials.gov NCT03604692 ↗Enrolled (actual)
41
Serious AEs
47.5%
Results posted
Nov 2024
Primary outcomePrimary: Phase 1: Number of Participants With DLTs — 0; 0; 0; 2 Participants
Summary
This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Phase 1: Number of Participants With DLTs |
0; 0; 0; 2; 0 | — |
| PRIMARY Phase 1: Recommended Phase 2 Dose (RP2D) |
1 | — |
| PRIMARY Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168) |
39.1 | — |
| SECONDARY Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration for SNDX-6352 |
30.7; 96.2; 1546.0; 10263.3; 12256.7; 22.9 | — |
| SECONDARY Phase 1: Observed Maximum Plasma Concentration for SNDX-6352 |
4.6; 13.7; 26.7; 84.0; 82.2; 3.5 | — |
| SECONDARY Phase 1: Time to Observed Maximum Plasma Concentration |
1.0; 1.5; 0.6; 0.9; 1.0; 0.6 | — |
| SECONDARY Phase 1: Changes From Baseline in Colony-Stimulating Factor-1 (CSF-1) and Interleukin (IL-34) Serum Concentrations |
2.0; 602.0; 364480.0; 544837.5; 451482.0; 69.0 | — |
| SECONDARY Phase 1: Percent Change From Baseline in Nonclassical Monocytes (CD14+CD16++) |
-41.7; -92.7; -95.7; -81.4; -66.7; 242.8 | — |
| SECONDARY Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA) |
0; 0; 1; 3; 2 | — |
| SECONDARY Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD |
78.3 | — |
| SECONDARY Phase 2: Failure Free Survival (FFS) |
16.9 | — |
| SECONDARY Phase 2: Duration of Response (DOR) |
9.53 | — |
| SECONDARY Phase 2: Sustained Response Rate (SRR) |
39.1 | — |
| SECONDARY Phase 2: Organ-specific Response Rate Based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD |
83.3; 18.8; 76.5; 0; 100.0; 33.3 | — |
| SECONDARY Phase 2: Number of Participants With a Joint and Fascia Response Based on Refined NIH Response Algorithm for cGVHD |
10; 7 | — |
| SECONDARY Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline |
12 | — |
| SECONDARY Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days |
5 | — |
| SECONDARY Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use |
— | — |
Eligibility Criteria
Key Inclusion Criteria
- Participant must be 6 years of age or older, at the time of signing the informed consent.
- Participants who are allogeneic hematopoietic stem cell transplant (HSCT) recipients with cGVHD requiring systemic immune suppression.
- Participants with active cGVHD who have received at least 2 lines of therapy. Participants 18 or older with active cGVHD who have erythematous rash involving >25% body surface area or a NIH mouth score of >4 must have received prior ibrutinib therapy.
a. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
- Participants may have persistent active acute and cGVHD manifestations (overlap syndrome), as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
- Karnofsky Performance Scale of ≥60 with a life expectancy of at least 3 months (if aged 16 years or older); Lansky Performance Score of ≥60 (if less than 16 years).
- Adequate organ and bone marrow functions.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent which includes compliance with the study requirements and restrictions.
Key Exclusion Criteria
- Has acute GVHD without manifestations of cGVHD.
- Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
- History or other evidence of severe illness, uncontrolled infection or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
- Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
- Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of enrollment, unless previously treated with curative intent and must be approved by Sponsor medical monitor (for example, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection).
- Female participants who are pregnant or breastfeeding.
- Previous exposure to study intervention or known allergy/sensitivity to study intervention.
- Taking agents other than a corticosteroid and one calcineurin inhibitor (CNI) for treatment of cGVHD (This does not include agents being prescribed expressly for the treatment of acute GVHD).
- Receiving an investigational treatment within 28 days of study entry.
Data sourced from ClinicalTrials.gov (NCT03604692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.